# ZIOPHARM Oncology Inc (ZIOP)

Source: https://www.quantisnow.com/company/ZIOP
Generated: 2026-11-11T11:49:42.397Z

- Ticker: ZIOP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: ziopharm.com

## About

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

## Latest ZIOP news and filings

- 2022-04-07 15:42 UTC [Leadership Update] [CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer](https://www.quantisnow.com/insight/carsgen-appoints-dr-raffaele-baffa-as-chief-medical-officer-2693310)
- 2022-01-26 16:19 UTC [Market Insight] [Ziopharm Rebrands As Alaunos Therapeutics](https://www.quantisnow.com/insight/ziopharm-rebrands-as-alaunos-therapeutics-2304088)
- 2022-01-26 13:29 UTC [Market Insight] [The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data](https://www.quantisnow.com/insight/the-daily-biotech-pulse-gileads-blood-cancer-studies-placed-on-2302289)
- 2022-01-26 12:28 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-amendments-to-articles-2301673)
- 2022-01-26 12:21 UTC [Market Insight] [Ziopharm Oncology Highlights Operational Progress & Rebrands To Alaunos Therapeutics](https://www.quantisnow.com/insight/ziopharm-oncology-highlights-operational-progress-rebrands-to-alaunos-therapeutics-2301640)
- 2022-01-26 12:00 UTC [Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics](https://www.quantisnow.com/insight/ziopharm-oncology-highlights-operational-progress-rebrands-to-alaunos-therapeutics-2301392)
- 2022-01-14 17:30 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Friday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-friday-2257151)
- 2022-01-04 21:05 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-entry-into-a-2210304)
- 2021-12-27 17:20 UTC [SEC Form 4] [SEC Form 4: De Groot Eleanor sold $25,568 worth of shares (20,132 units at $1.27) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 237,106 units (tax withholding)](https://www.quantisnow.com/insight/sec-form-4-de-groot-eleanor-sold-25568-worth-of-2184342)
- 2021-12-17 21:38 UTC [Market Insight] [12 Health Care Stocks Moving In Friday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-fridays-after-market-session-2159713)
- 2021-12-13 11:06 UTC [SEC Form 4] [SEC Form 4 filed by Lackey Melinda](https://www.quantisnow.com/insight/sec-form-4-filed-by-lackey-melinda-2128923)
- 2021-12-09 19:33 UTC [SEC Form 3] [SEC Form 3 filed by new insider Lackey Melinda](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-lackey-melinda-2121087)
- 2021-12-06 21:32 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-after-market-session-2102751)
- 2021-11-29 23:40 UTC [SEC Form 3] [SEC Form 3 filed by new insider Wong Michael](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-wong-michael-2070814)
- 2021-11-17 21:53 UTC [SEC Form 4] [SEC Form 4: Boyle Kevin S. Sr. bought $14,000 worth of shares (10,000 units at $1.40), increasing direct ownership by 1% to 885,000 units](https://www.quantisnow.com/insight/sec-form-4-boyle-kevin-s-sr-bought-14000-worth-2025100)
- 2021-11-09 13:05 UTC [Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting](https://www.quantisnow.com/insight/ziopharm-oncology-presents-preclinical-data-supporting-tcr-t-library-approach-at-1980100)
- 2021-11-09 12:43 UTC [Analyst Coverage Reiterated] [Raymond James reiterated coverage on ZIOPHARM Oncology with a new price target](https://www.quantisnow.com/insight/raymond-james-reiterated-coverage-on-ziopharm-oncology-with-a-new-1979561)
- 2021-11-08 21:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ZIOPHARM Oncology Inc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ziopharm-oncology-inc-1976372)
- 2021-11-08 21:10 UTC [Earnings Date] [Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/ziopharm-oncology-reports-third-quarter-2021-financial-results-and-provides-1976325)
- 2021-11-05 20:09 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-leadership-update-1969839)
- 2021-11-01 20:30 UTC [Earnings Date] [Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021](https://www.quantisnow.com/insight/ziopharm-oncology-to-report-third-quarter-financial-results-on-november-1941050)
- 2021-10-12 17:40 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by ZIOPHARM Oncology Inc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-ziopharm-oncology-inc-amendment-1866204)
- 2021-10-04 22:11 UTC [SEC Form 4] [SEC Form 4: Vieser Jaime bought $191,000 worth of shares (100,000 units at $1.91), increasing direct ownership by 17% to 705,321 units](https://www.quantisnow.com/insight/sec-form-4-vieser-jaime-bought-191000-worth-of-shares-1839215)
- 2021-10-01 20:06 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-leadership-update-1832621)
- 2021-09-27 20:05 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-costs-associated-with-1813067)
- 2021-09-27 20:05 UTC [Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway](https://www.quantisnow.com/insight/ziopharm-oncology-announces-strategic-reduction-in-workforce-and-extension-in-1813019)
- 2021-09-03 21:25 UTC [SEC Form 4] [SEC Form 4: Hagen Heidi bought $41,835 worth of Common Stock (23,770 units at $1.76), increasing direct ownership by 19% to 145,889 units](https://www.quantisnow.com/insight/sec-form-4-hagen-heidi-bought-41835-worth-of-common-1741478)
- 2021-09-03 21:23 UTC [SEC Form 4] [SEC Form 4: Weis Holger bought $91,500 worth of Common Stock (50,000 units at $1.83), increasing direct ownership by 71% to 120,167 units](https://www.quantisnow.com/insight/sec-form-4-weis-holger-bought-91500-worth-of-common-1741467)
- 2021-09-03 21:22 UTC [SEC Form 4] [SEC Form 4: Postma Robert W bought $129,750 worth of Common Stock (75,000 units at $1.73), increasing direct ownership by 2% to 1,201,870 units](https://www.quantisnow.com/insight/sec-form-4-postma-robert-w-bought-129750-worth-of-1741451)
- 2021-09-03 21:21 UTC [SEC Form 4] [SEC Form 4: Huang James bought $171,000 worth of Common Stock (100,000 units at $1.71), increasing direct ownership by 1,200% to 108,333 units](https://www.quantisnow.com/insight/sec-form-4-huang-james-bought-171000-worth-of-common-1741446)
- 2021-09-01 20:05 UTC [Conference Announcement] [Ziopharm Oncology to Participate in September Investor Conferences](https://www.quantisnow.com/insight/ziopharm-oncology-to-participate-in-september-investor-conferences-1731799)
- 2021-08-31 20:42 UTC [SEC Form 4] [SEC Form 4: Boyle Kevin S. Sr. was granted 875,000 units of Common Stock](https://www.quantisnow.com/insight/sec-form-4-boyle-kevin-s-sr-was-granted-875000-1726882)
- 2021-08-31 20:37 UTC [SEC Form 3] [SEC Form 3 filed by new insider Boyle Kevin S. Sr.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-boyle-kevin-s-1726853)
- 2021-08-30 21:25 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-leadership-update-financial-1721825)
- 2021-08-30 12:30 UTC [Earnings Date] [Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions](https://www.quantisnow.com/insight/ziopharm-oncology-appoints-kevin-s-boyle-sr-as-chief-executive-1718851)
- 2021-08-13 20:58 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ZIOPHARM Oncology Inc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ziopharm-oncology-inc-1668981)
- 2021-08-12 20:57 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-entry-into-a-1664619)
- 2021-08-10 10:27 UTC [Analyst Downgrade] [ZIOPHARM downgraded by Raymond James](https://www.quantisnow.com/insight/ziopharm-downgraded-by-raymond-james-1647172)
- 2021-08-10 09:08 UTC [Analyst Downgrade] [ZIOPHARM Oncology downgraded by Raymond James with a new price target](https://www.quantisnow.com/insight/ziopharm-oncology-downgraded-by-raymond-james-with-a-new-price-1646793)
- 2021-08-09 21:04 UTC [SEC Form 8-K] [ZIOPHARM Oncology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ziopharm-oncology-inc-filed-sec-form-8-k-results-of-operations-1645747)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ZIOP
- Earnings history: https://www.quantisnow.com/earnings/ZIOP
- Dividend history: https://www.quantisnow.com/dividends/ZIOP
- Insider transactions: https://www.quantisnow.com/insiders/ZIOP
- Options chain: https://www.quantisnow.com/options/ZIOP
- SEC 8-K filings only: https://www.quantisnow.com/company/ZIOP/8-k
- RSS and alerts for ZIOP: https://www.quantisnow.com/docs/rss-feeds.md